ArticleFrontiers in neuroscience2025
Key considerations for ELISA-based quantification of diverse amyloid beta forms in murine brain homogenates.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Amyloid-beta fibrils as active contributors to synaptic dysfunction in Alzheimer's disease.Acta pharmacologica Sinica · 2026Article
- Curcumin as theranostics: imaging-guided therapeutics in oncology and neurodegenerative diseases.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enzyme-Linked Immunosorbent Assay (ELISA) is a widely utilized method for quantifying amyloid beta (Aβ) levels in various biological samples, including brain homogenates. Aβ exist in multiple structural forms: monomers, soluble oligomers, protofibrils, and fibrils, each exhibiting distinct biochemical properties and degrees of neurotoxicity. Their toxic potential also varies by localization, whether intracellular, membrane-bound, or extracellular. Accurate detection and quantification of these diverse Aβ species and localizations are critical for understanding their roles in Alzheimer's disease (AD) pathology. However, suboptimal ELISA configurations and misinterpretations of results can lead to misleading conclusions. This study highlights key considerations for optimizing ELISA protocols specifically for detecting distinct Aβ species and localizations, with a focus on applications in mouse brain tissue. We also provide guidance on antibody selection to improve selectivity and specificity of Aβ detection, ultimately enhancing the reliability and interpretability of ELISA-based Aβ measurements.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.